Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2022

May 16, 2022

SELL
$14.54 - $21.5 $597,594 - $883,650
-41,100 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$26.01 - $38.22 $80,631 - $118,482
3,100 Added 8.16%
41,100 $1.32 Million
Q1 2021

May 17, 2021

BUY
$29.24 - $42.03 $1.11 Million - $1.6 Million
38,000 New
38,000 $1.28 Million

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $300M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Css LLC Portfolio

Follow Css LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Css LLC, based on Form 13F filings with the SEC.

News

Stay updated on Css LLC with notifications on news.